Fecha de publicación: 05/01/2023 Fuente: WIPO Rice In alternative embodiments, provided are methods for treating or ameliorating hyperactive ZAP70 kinase-related diseases or conditions, including any disease or conditions mediated by hyperactive T cells or disease or condition whose pathology is initiated, aggravated or mediated by hyperactive T cells, such as autoimmune disease (including for example, an autoimmune disease requiring allogeneic hematopoietic cell transplantation (HCT) in patients, rheumatoid arthritis (RA), inflammatory bowel disease (IBD), Crohn's disease, type 1 diabetes, multiple sclerosis, uncontrollable bullous pemphigoid, colitis, celiac disease, dermatitis and proteinuria), organ transplant rejection, graft-versus-host disease (GVHD) and/or B cell chronic lymphocytic leukemia (CLL). In alternative embodiments, methods as provided herein comprise administering to an individual in need thereof the FDA-approved cancer drug sunitinib (or SUTENT™), or salts or formulations thereof, for example sunitinib malate.